Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dropropizine→

Dropropizine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
17692-31-8
Molecular formula
C13H20N2O2
Molecular weight
236.31 g/mol
Drug class
Non-opioid antitussiveperipheral cough suppressant
Mechanism of action
Suppresses cough through peripheral modulation of airway sensory pathways; the exact molecular target and mechanism are not fully established. It does not act as a classical opioid mu-receptor agonist.
Indications / reported uses
  • Symptomatic treatment of dry, non-productive cough in countries where dropropizine products are authorised; not intended to suppress productive cough where expectoration is required

Sources: NLM MeSH — Dropropizine · PubMed — Dropropizine antitussive · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dropropizine Environmental Risk Assessment (ERA) (the Dropropizine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.